Zacks Research Expects Lower Earnings for Bausch Health Cos

Bausch Health Cos Inc. (NYSE:BHC) – Equities researchers at Zacks Research reduced their Q1 2027 earnings per share estimates for Bausch Health Cos in a research note issued on Monday, October 27th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.87 per share for the quarter, down from their prior forecast of $0.88. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q3 2027 earnings at $1.20 EPS and FY2027 earnings at $4.34 EPS.

Other equities research analysts have also issued reports about the company. Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.00.

Bausch Health Cos Stock Down 0.2%

Shares of Bausch Health Cos stock opened at $6.19 on Tuesday. The stock’s fifty day moving average is $6.76 and its 200-day moving average is $6.08. The firm has a market capitalization of $2.29 billion, a PE ratio of 23.79 and a beta of 0.43. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $9.85.

Bausch Health Cos (NYSE:BHC) last announced its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.07). The company had revenue of $2.57 billion for the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.

Insiders Place Their Bets

In other Bausch Health Cos news, Director John Paulson purchased 34,721,118 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the transaction, the director owned 70,755,869 shares of the company’s stock, valued at approximately $636,802,821. This represents a 96.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders acquired 37,964,167 shares of company stock worth $333,757,793 over the last quarter. 19.97% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Goldentree Asset Management LP increased its position in Bausch Health Cos by 13.2% in the 2nd quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock worth $227,848,000 after purchasing an additional 4,004,889 shares during the last quarter. Paulson & CO. Inc. boosted its stake in shares of Bausch Health Cos by 24.0% during the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after acquiring an additional 6,352,667 shares in the last quarter. Nomura Holdings Inc. boosted its stake in shares of Bausch Health Cos by 106.2% during the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock worth $151,366,000 after acquiring an additional 12,050,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Bausch Health Cos by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company’s stock worth $76,152,000 after acquiring an additional 61,621 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. boosted its stake in shares of Bausch Health Cos by 14.9% during the 2nd quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock worth $52,005,000 after acquiring an additional 1,010,987 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.